Home / VCNX : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does VCNX make money? Does VCNX have pricing power? What's the Earnings Whisper? Will VCNX profit more as the business scales? What is VCNX's management track record? Is VCNX's current price justified?

Vaccinex, Inc.

$1.06 -$0.07 (-6.19%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$1.05

Day Range

$1.05$1.06

Year Range

$0.31$1.5

Market Cap

2.84M

AVG Volume

1.75K

Trailing/Forward PE

-0.54/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

Other OTC

Revenue (USD)

VCNX Revenue (USD) by quarter
Period	Revenue (USD)
24 Q4	213K
24 Q3	52K
24 Q2	232K
24 Q1	104K
23 Q4	-386K
23 Q3	20K
23 Q2	0
23 Q1	550K
22 Q4	50K
22 Q3	50K

Net Income (USD)

VCNX Net Income (USD) by quarter
Period	Net Income (USD)
24 Q4	-3.37M
24 Q3	-5.73M
24 Q2	-5.63M
24 Q1	-3.9M
23 Q4	-3.32M
23 Q3	-4.91M
23 Q2	-7.06M
23 Q1	-4.94M
22 Q4	-5.08M
22 Q3	-4.76M

Operating Income (USD)

VCNX Operating Income (USD) by quarter
Period	Operating Income (USD)
24 Q4	-3.39M
24 Q3	-4.55M
24 Q2	-5.72M
24 Q1	-5.07M
23 Q4	-4.99M
23 Q3	-5.83M
23 Q2	-7.08M
23 Q1	-4.99M
22 Q4	-5.12M
22 Q3	-4.79M

EBITDA (USD)

VCNX EBITDA (USD) by quarter
Period	EBITDA (USD)
24 Q4	-3.35M
24 Q3	-5.71M
24 Q2	-5.61M
24 Q1	-3.84M
23 Q4	-2.91M
23 Q3	-4.88M
23 Q2	-7.03M
23 Q1	-4.93M
22 Q4	-5.03M
22 Q3	-4.69M

Cash Flows (USD)

VCNX Cash Flows (USD) by quarter
Period	Cash Flows (USD)
24 Q4	-3.93M
24 Q3	-3.21M
24 Q2	-4.43M
24 Q1	-4.63M
23 Q4	-3.59M
23 Q3	-3.11M
23 Q2	-5.51M
23 Q1	-5.09M
22 Q4	-4.6M
22 Q3	-4.2M

EPS (USD)

VCNX EPS (USD) by quarter
Period	EPS (USD)
24 Q4	-1.61
24 Q3	-2.83
24 Q2	-3.1
24 Q1	-2.94
23 Q4	-8.44
23 Q3	-15.26
23 Q2	-24.54
23 Q1	-20.79
22 Q4	-25.06
22 Q3	-23.42

Expenses (USD)

VCNX Expenses (USD) by quarter
Period	Expenses (USD)
24 Q4	3.6M
24 Q3	4.61M
24 Q2	5.97M
24 Q1	5.18M
23 Q4	4.96M
23 Q3	5.87M
23 Q2	7.08M
23 Q1	5.58M
22 Q4	5.34M
22 Q3	4.89M

Cash & Debt (USD)

VCNX Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
24 Q4	1.11M
24 Q3	2.91M
24 Q2	233K
24 Q1	2.97M
23 Q4	1.53M
23 Q3	127K
23 Q2	1.91M
23 Q1	3.32M
22 Q4	6.39M
22 Q3	7.19M

Debt ratios

VCNX Debt ratios by quarter
Period	Debt ratios
24 Q4	0.06
24 Q3	0.16
24 Q2	0.01
24 Q1	0.15
23 Q4	0.07
23 Q3	-0.02
23 Q2	0.06
23 Q1	0.14
22 Q4	0.3
22 Q3	0.35

Margins

VCNX Margins by quarter
Period	Margins
24 Q4	100%
24 Q3	100%
24 Q2	100%
24 Q1	74.04%
23 Q4	6.87%
23 Q3	-55%
23 Q1	94.36%
22 Q4	100%
22 Q3	100%
21 Q4	95.18%

Return on Capital

VCNX Return on Capital by quarter
Period	Return on Capital
24 Q4	135.61%
24 Q3	433.91%
24 Q2	196.61%
24 Q1	-146.78%
23 Q4	143.53%
23 Q3	126.96%
23 Q2	1669.03%
23 Q1	-205.75%
22 Q4	-97.79%
22 Q3	-75.32%

Shares Outstanding

VCNX Shares Outstanding by quarter
Period	Shares Outstanding
24 Q4	2.1M
24 Q3	2.03M
24 Q2	1.82M
24 Q1	1.33M
23 Q4	392.78K
23 Q3	321.92K
23 Q2	280.16K
23 Q1	236.28K
22 Q4	202.62K
22 Q3	203.16K

Book Value Per Share (USD)

VCNX Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
24 Q4	-1.19
24 Q3	-0.65
24 Q2	-1.58
24 Q1	2
23 Q4	-5.88
23 Q3	-12.02
23 Q2	-1.51
23 Q1	10.16
22 Q4	25.63
22 Q3	31.1

Total Assets (USD)

VCNX Total Assets (USD) by quarter
Period	Total Assets (USD)
24 Q4	2.6M
24 Q3	4.85M
24 Q2	2.37M
24 Q1	7.37M
23 Q4	3.63M
23 Q3	2.56M
23 Q2	3.08M
23 Q1	4.89M
22 Q4	7.98M
22 Q3	8.61M

Employee Count

VCNX Employee Count by quarter
Period	Employee Count
2024	23
2023	37
2022	38
2021	39
2020	39
2019	45
2018	44

Free Cash Flow Yield

VCNX Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-728.49%
Sep 26	-735.43%
Sep 26	-1029.6%
Aug 26	-772.2%
Aug 26	-702%
Aug 26	-930.36%
Aug 26	-780%
Jul 26	-908.47%
Jul 26	-654.4%
Jul 26	-671.48%
Jul 26	-598.6%
Jul 26	-757.06%
Jun 26	-1002.85%
Jun 26	-695.67%
Jun 26	-764.55%
Jun 26	-772.2%
May 26	-772.2%
May 26	-772.2%
May 26	-702%
May 26	-764.55%
May 26	-772.2%
Apr 26	-735.43%
Apr 26	-772.2%
Apr 26	-772.2%
Apr 26	-772.2%
Mar 26	-648.9%
Mar 26	-869.59%
Mar 26	-1103.14%
Mar 26	-968.27%
Feb 26	-749.71%
Feb 26	-749.71%
Feb 26	-617.76%
Feb 26	-643.5%
Jan 26	-563.65%
Jan 26	-580.6%
Jan 26	-572%
Jan 26	-772.2%
Jan 26	-683.36%
Dec 25	-708.44%
Dec 25	-977.46%
Dec 25	-1544.08%
Dec 25	-1103.14%
Nov 25	-1103.3%
Nov 25	-1103.14%
Nov 25	-1105.51%
Nov 25	-1104.72%
Oct 25	-1223.57%
Oct 25	-878.79%
Oct 25	-1608.74%
Oct 25	-1514.11%
Oct 25	-1206.56%
Sep 25	-1043.51%
Sep 25	-1103.14%
Sep 25	-1218.94%
Sep 25	-1456.97%
Aug 25	-1544.39%
Aug 25	-772.2%
Aug 25	-986.08%
Aug 25	-1103.14%
Aug 25	-977.55%
Jul 25	-1087.6%
Jul 25	-848.57%
Jul 25	-821.49%
Jul 25	-1103.93%
Jun 25	-1057.8%
Jun 25	-1087.6%
Jun 25	-941.7%
Jun 25	-897.9%
May 25	-839.34%
May 25	-1135.58%
May 25	-742.5%
May 25	-1135.58%
May 25	-1152.53%
Apr 25	-858%
Apr 25	-1043.51%
Apr 25	-1118.38%
Apr 25	-1304.77%
Mar 25	-1043.82%
Mar 25	-1373.44%
Mar 25	-1057.92%
Mar 25	-841.79%
Feb 25	-711.69%
Feb 25	-760.06%
Feb 25	-899.84%
Feb 25	-767.51%
Jan 25	-652.39%
Jan 25	-669.11%
Jan 25	-724.87%
Jan 25	-680.75%
Jan 25	-652.39%
Dec 24	-718.22%
Dec 24	-646.99%
Dec 24	-212.16%
Dec 24	-200.22%
Nov 24	-207.11%
Nov 24	-216.26%
Nov 24	-247.74%
Nov 24	-279.82%
Nov 24	-294.05%
Oct 24	-256.64%

Price to Sales

VCNX Price to Sales by quarter
Period	Price to Sales
Sep 26	3.7
Sep 26	3.67
Sep 26	2.62
Aug 26	3.49
Aug 26	3.84
Aug 26	2.9
Aug 26	3.46
Jul 26	2.97
Jul 26	4.12
Jul 26	4.02
Jul 26	4.51
Jul 26	3.56
Jun 26	2.69
Jun 26	3.88
Jun 26	3.53
Jun 26	3.49
May 26	3.49
May 26	3.49
May 26	3.84
May 26	3.53
May 26	3.49
Apr 26	3.67
Apr 26	3.49
Apr 26	3.49
Apr 26	3.49
Mar 26	4.16
Mar 26	3.1
Mar 26	2.44
Mar 26	2.79
Feb 26	3.6
Feb 26	3.6
Feb 26	4.37
Feb 26	4.19
Jan 26	4.78
Jan 26	4.64
Jan 26	4.71
Jan 26	3.49
Jan 26	3.95
Dec 25	3.81
Dec 25	2.76
Dec 25	1.75
Dec 25	2.44
Nov 25	2.44
Nov 25	2.44
Nov 25	2.44
Nov 25	2.44
Oct 25	2.2
Oct 25	3.07
Oct 25	1.68
Oct 25	1.78
Oct 25	2.24
Sep 25	2.58
Sep 25	2.44
Sep 25	2.21
Sep 25	1.85
Aug 25	1.75
Aug 25	3.49
Aug 25	2.73
Aug 25	2.44
Aug 25	2.76
Jul 25	2.48
Jul 25	3.18
Jul 25	3.28
Jul 25	2.44
Jun 25	2.55
Jun 25	2.48
Jun 25	2.86
Jun 25	3
May 25	3.21
May 25	2.37
May 25	3.63
May 25	2.37
May 25	2.34
Apr 25	3.14
Apr 25	2.58
Apr 25	709.42
Apr 25	608.08
Mar 25	760.1
Mar 25	577.67
Mar 25	749.96
Mar 25	942.52
Feb 25	1114.81
Feb 25	1043.86
Feb 25	881.71
Feb 25	1033.73
Jan 25	1216.15
Jan 25	1185.75
Jan 25	1094.54
Jan 25	1165.48
Jan 25	1216.15
Dec 24	1104.67
Dec 24	1226.29
Dec 24	3739.67
Dec 24	3962.63
Nov 24	3830.88
Nov 24	3668.73
Nov 24	3202.53
Nov 24	-187.81
Nov 24	-178.72
Oct 24	-204.77

Price to Book

VCNX Price to Book by quarter
Period	Price to Book
Aug 24	2.29
Aug 24	2.61
Jul 24	3.36
Jul 24	3.55
Jul 24	3.29
Jul 24	3.32
Jun 24	3.24
Jun 24	3.05
Jun 24	3.43
Jun 24	3.71
May 24	3.39
May 24	2.7
May 24	2.77
Aug 23	5.38
Aug 23	5.58
Jul 23	5.79
Jul 23	6.41
Jul 23	6.41
Jul 23	7.44
Jun 23	7.44
Jun 23	7.24
Jun 23	7.86
Jun 23	9.51
Jun 23	8.68
May 23	8.48
May 23	8.27
May 23	3.28
May 23	2.87
Apr 23	2.95
Apr 23	3.28
Apr 23	3.52
Apr 23	3.28
Mar 23	3.28
Mar 23	2.77
Mar 23	2.77
Mar 23	2.9
Mar 23	3.44
Feb 23	3.11
Feb 23	3.44
Feb 23	3.85
Feb 23	3.98
Jan 23	4.05
Jan 23	3.98
Jan 23	4.32
Jan 23	4.32
Dec 22	4.32
Dec 22	4.59
Dec 22	4.73
Dec 22	4.39
Dec 22	4.39
Nov 22	2.97
Nov 22	3.51
Nov 22	2.27
Nov 22	2.16
Oct 22	2.19
Oct 22	1.85
Oct 22	2.04
Oct 22	2.23
Sep 22	1.89
Sep 22	1.82
Sep 22	3.03
Sep 22	2.76
Sep 22	3.03
Aug 22	3.75
Aug 22	3.78
Aug 22	2.6
Aug 22	2.44
Jul 22	2.48
Jul 22	2.65
Jul 22	2.79
Jul 22	2.79
Jul 22	2.46
Jun 22	2.7
Jun 22	2.53
Jun 22	3
Jun 22	3.19
May 22	3
May 22	2.84
May 22	4.82
May 22	5.1
Apr 22	5.34
Apr 22	5.06
Apr 22	4.98
Apr 22	5.26
Apr 22	5.22
Mar 22	3.6
Mar 22	3.78
Mar 22	3.11
Mar 22	2.82
Feb 22	3.76
Feb 22	3.26
Feb 22	4.59
Feb 22	4.27
Jan 22	2.93
Jan 22	2.69
Jan 22	2.9
Jan 22	2.9
Dec 21	2.69
Dec 21	3.37
Dec 21	3.42

No video analysis for this stock yet. Request one from our team.

News: VCNX

globenewswire.com · 8 Jul 2026

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026

ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new biomarker data from its Phase 1b/2 trial to support plans for an enlarged randomized phase 2B SIGNAL-AD study of pepinemab for treatment for early Alzheimer's disease at the Alzheimer's Association International Conference in London, United Kingdom, on July 13, 2026.

AI Analysis

Vaccinex, Inc.

Video analysis: VCNX

News: VCNX

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026

Similar companies